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Abstract Significant advances in cardiac intensive care in-
cluding extracorporeal life support have enabled children with
complex congenital heart disease and end-stage heart failure
to be supported while awaiting transplantation. With an in-
creasing number of survivors after heart transplantation in
children, the complications from long-term immunosuppres-
sion, including renal insufficiency, are becoming more appar-
ent. Severe renal dysfunction after heart transplant is defined
by a serum creatinine level>2.5 mg/dL (221 μmol/L), and/or
need for dialysis or renal transplant. The degree of renal
dysfunction is variable and is progressive over time. About
3–10 % of heart transplant recipients will go on to develop
severe renal dysfunction within the first 10 years post-
transplantation. Multiple risk factors for chronic kidney dis-
ease post-transplant have been identified, which include pre-
transplant worsening renal function, recipient demographics
and morbidity, peri-transplant haemodynamics and long-term
exposure to calcineurin inhibitors. Renal insufficiency in-
creases the risk of post-transplant morbidity and mortality.
Hence, screening for renal dysfunction pre-, peri- and post-
transplantation is important. Early and timely detection of
renal insufficiency may help minimize renal insults, and allow
prompt implementation of renoprotective strategies. Close
monitoring and pre-emptive management of renal dysfunction
is an integral aspect of peri-transplant and subsequent post-
transplant long-term care.
Keywords Renal failure . Chronic kidney disease . Renal
insufficiency . Calcineurin inhibitor . Complications .
Creatinine clearance . Bridging to transplant
Introduction
Significant advances in heart transplantation medicine have
improved survival outcome in children with end-stage heart
disease [1–3]. In addition, extracorporeal mechanical circula-
tory support (MCS) offers these children with single- or multi-
organ failure an opportunity to wait for a suitable organ to
become available. With the introduction of highly effective
immunosuppressive treatment, the 1-year and long-term graft
survival rates have markedly improved. However, with im-
proved survival, several detrimental effects of long-term im-
munosuppression, in particular renal dysfunction and conse-
quent chronic renal insufficiency (CRI), have emerged, all of
which increase the risk of post-transplant morbidity and mor-
tality [4–8]. Renal insufficiency is an important cause of
morbidity after paediatric transplantation, with the majority
of patients experiencing at least mild renal dysfunction
[9–12]. The specific focus of this review is acute kidney injury
(AKI) following heart transplantation in children; chronic
kidney disease (CKD) requiring dialysis and future renal
transplant are also briefly discussed.
Defining the spectrum of renal dysfunction
Acute kidney injury
Acute kidney injury may be defined using the AKI diagnostic
criteria and staging system as proposed by the Acute Kidney
Injury Network (AKIN), which is based on acute alterations in
serum creatinine and/or urine output [13]. AKI immediately
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post-transplant may be defined as a ≥50 % increase in the
baseline pre-operative creatinine value in the first 1–2 post-
operative weeks and/or the need for early post-operative
dialysis. In one adult study, post-transplant acute renal fail-
ure was defined on the basis of a serum creatinine level of
≥0.3 mg/dL (26.4 μmol/L) or a ≥50 % rise in serum creat-
inine from the pre-operative value within the first 7 days
after heart transplant (HT) and/or the need for early post-
operative dialysis [14].
Chronic renal insufficiency
In the ISHLT (The International Society for Heart and
Lung Transplantation) Registry, CRI is defined as a serum
creatinine level of >2.5 mg/dL (221 μmol/L) and has been
used to describe post-transplant renal morbidity [2]. CKD
is defined as a glomerular filtration rate (GFR) of
<60 mL/min/1.73 m2 for at least 3 months and/or signs
of kidney damage for ≥3 months [15]. CKD, further
defined in stages (1–5) depending on severity, may be
used to categorize degrees of renal impairment after
transplant.
Severity
The degree of severity of renal dysfunction may be variable
after HT. In the ISHLT Registry, severe renal dysfunction is
defined as a serum creatinine level of >2.5 mg/dL
(221 μmol/L) and the need for dialysis or renal transplant
[2, 3]. End-stage renal disease (ESRD) has been defined by
an ongoing need for dialysis and/or having had renal
transplant.
Measuring renal dysfunction: challenges
The GFR remains the most widely accepted indicator of renal
function, and its determination by nuclear medicine scintigra-
phy is the gold standard measurement method. However, as
formal GFR measurement is not practical for routine monitor-
ing, the most commonly used method is the estimated GFR
(eGFR) by the Schwartz method [16]. It is important to note
that there are significant limitations in accurately assessing
renal insufficiency with this method. In particular, identifying
mild to moderate renal dysfunction may be challenging. Stud-
ies in the transplant population comparing the two methods
have shown that eGFR significantly underestimates the bur-
den of renal insufficiency [10, 12, 17]. In a longitudinal study
of children post-HT, eGFR overestimated the measured GFR
(by nuclear medicine scintigraphy) by 33±26 mL/kg/1.73 m2
[10]. English et al. found that the GFR estimated by creatinine
clearance consistently overestimated the GFR and that the
latter was >2 standard deviations below the mean normal
value in 38 % of their study cohort [17]. Creatinine is a
function of muscle mass, and height is a surrogate for lean
body mass. Transplant recipients may have normal serum
creatinine values in the face of incipient renal dysfunction
because creatinine generation may be low due to reduced
muscle mass and poor nutritional state from end-stage heart
failure, possibly explaining the discrepancy in eGFR and
measured GFR in the above-mentioned studies. Further-
more, it can be challenging to measure renal function in
infants [18] and children aged <2 years, and in this age
group GFR may be better expressed as the percentage of
normal GFR for age and gender (GFR %>75, indicating
normal renal function) [9].
Prevalence and progression of renal dysfunction
Renal dysfunction is one of the most common medical mor-
bidities post-solid organ transplantation [3, 19–21]. Although
the cause may bemultifactorial in origin, it is mainly related to
the side-effects of long-term immunosuppression [4, 7, 17, 19,
22]. The prevalence of CKD following non-renal paediatric
transplantation is often underestimated—and is often diag-
nosed late. Based on published studies, the prevalence of renal
dysfunction after lung transplant (LT) is higher than after HT,
or even after heart–lung transplant (H–LT), and is perhaps
related to the higher level of immunosuppression in LT recip-
ients [2, 3, 11]
Acute kidney injury
In the immediate post-transplant period, AKI may result fol-
lowing renal hypoperfusion and a low cardiac output state in
association with long graft ischaemic times [23], isolated right
heart failure [24] and acute graft failure [25]. AKI may also be
seen in the context of acute drug-induced nephrotoxicity
related to the use of calcineurin inhibitors (CNI) and/or ami-
noglycoside antibiotics, or it may be seen as part of multi-
organ failure due to sepsis. In a national UNOS Registry
study, Tang et al. found that 4.8 % of paediatric HT recipients
developed AKI requiring dialysis [8]. AKI usually tends to
improve with renal replacement therapy (RRT) and very rarely
may be the cause of death in the first month after HT [3].
However, a paediatric HT study [8] and an adult study [14]
have shown that AKI in the first week post-HTassociatedwith
a longer duration of mechanical support increased hospital
stay and increased early mortality.
AKI is not limited to the immediate peri-operative period
and can occur at any time in the post-transplant period; it is
usually associated with changes in immunosuppressive drug
levels, graft function, rejection episodes, dehydration or
infection.
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Chronic renal insufficiency
Multiple single-centre studies and ISHLT Registry data have
demonstrated a variable progression of renal dysfunction over
time, with most studies showing an early decline in the first 6–
12 post-transplantation months followed by a gradual decline
over subsequent years [9, 17, 26–28]. On longitudinal follow-
up of renal function using measured GFR, Bharat et al. found
at least mild renal impairment in 16 and 66 % of patients at 1
and 5 years after HT, respectively [10]. In another single-
centre study with a median follow-up of 5 years post-HT,
there was progressive increase in renal insufficiency from 17
to 21% and then to 29% at 1, 3 and 5 years, respectively [27].
In a 10-year U.S. study of paediatric HT recipients (age
<18 years) from 1990 to 1999 who survived for>1 year, 3 %
developed ESRD during the mean follow-up period of 7 years
(range 1–14 years). The 5-year actuarial risk for ESRD was
0.9 % and that for CRI was 4 %, both increasing to 4.3 and
11.8 % at 10 years, respectively [5]. In a more recent study
from the PHTS registry, 1.4 % developed ESRD over a
follow-up period of 4 years, and freedom from late renal
dysfunction was 71 and 57 % at 5 and 10 years, respectively
[6]. In the ISHLT Fifteenth Official Paediatric Registry Report
2012, 10 % of HT recipients required RRT in the form of
dialysis or renal transplant by 15 years post-transplant [3].
In contrast, very few studies have shown an improvement or
even long-term stability of renal function over time [29, 30].
Phan et al. reported an improvement in the post-operative peri-
od, presumably as a result of better cardiac output and improved
renal perfusion [30]. In a single-centre study of thoracic trans-
plant recipients, among whom HT recipients predominated,
Pradhan et al. found a decline in the mean percentage of normal
eGFR in the first 6 months after transplantation, following
which the level remained relatively stable for nearly 9 years.
However, the GFR % (percent normal for age and gender),
showed a significant decline over time within all age brackets,
with the maximum decline occurring in the first 2 years despite
adjustment for improvement in nutritional state. In addition, the
percentage of patients with a GFR % of >75 dropped from
78 % at the time of transplant to 45 % at 1 year, 29 % at
2 years and only 14 % at 5 years after transplantation [9].
The variability in the above studies reflects the variation in
indicators used for measuring renal dysfunction, the short-
comings in estimating equations based on serum creatinine
and the differences in immunosuppression protocols in differ-
ent centres. These studies are tabulated in Table 1.
Timing/pathophysiology/mechanisms of kidney injury
The factors contributing to kidney injury in paediatric HT
recipients are shown in Fig. 1.
Pre-existing (pre-transplant) renal insufficiency
Pre-existing renal insufficiency, either pre-transplant or peri-
transplant, is common and may be seen in about 2.5–42 % of
the study cohorts, depending on the definition used for renal
dysfunction [6, 8, 9, 27, 30, 31]. Various pathophysiological
mechanisms, such as renal neurohormonal activation and
paediatric cardiorenal syndrome, are postulated in the context
of chronic heart failure [32]. Pre-transplant renal insufficiency,
however, has an important influence on post-operative renal
insufficiency—the worse the degree of impaired pre-operative
renal function, the higher the chances of post-operative renal
dysfunction [4, 8] [30]. However, accurate assessment of renal
function in the pre-transplant phase to ensure that there is
adequate renal reserve is difficult because of limitations in
GFR measurement. Tang et al. reported that 60 % of those on
pre-transplant dialysis required it in the post-operative period
and that those that needed both pre- and post-transplant dial-
ysis had much worse longitudinal survival outcomes as com-
pared to those who had needed it only either pre- or post-HT
[8].
Early after transplant
Varying degrees of AKI are commonly seen in the immediate
peri-operative period [8, 10]. Multiple factors are responsible,
including pre-transplant renal function, the transplant surgery
itself with cardiopulmonary bypass, peri- and post-transplant
haemodynamic state, graft function and finally nephrotoxicity
from acute exposure to CNI and other nephrotoxic drugs.
Transplant surgery Renal function may be affected by the
transplant surgery itself, which involves cardiopulmonary by-
pass and aortic cross clamp against a background of a com-
promised general state resulting from the end-stage heart
disease. In addition, there may be large volume shifts and
aggressive diuresis in the immediate peri-operative period.
In particular, children undergoing a high-risk transplant fol-
lowing single ventricle palliation, for example following
Fontan surgery, who need longer duration of cardiopulmonary
bypass may be vulnerable to compromised renal function
[33].
Peri- and post-transplant haemodynamic state and graft
function In the post-operative period, particularly with HT
recipients, renal perfusion is entirely dependent on the graft
function. In addition, there may be significant capillary leak
post-HT. Peri- and post-transplant haemodynamic state and
allograft function changes, resulting in hypotension requiring
inotropic support, may lead to variability in renal perfusion [4,
23, 25] and aggravate any microcirculatory abnormalities and
increases in renovascular resistance caused by acute exposure
to CNI agents.
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Other nephrotoxic drugs in the immediate post-transplant
period may further contribute to acute renal dysfunction. AKI
post-HT, especially in those after failed palliation following
congenital heart disease (CHD) necessitating haemodialysis,
portends a poor outcome [33].
Mechanical circulatory support in the peri-transplant
period and renal function
In children with worsening heart failure, poor renal function
associated with low cardiac output state is one of the
Fig. 1 Factors contributing to
kidney injury in paediatric heart
transplant recipients. ECMO
Extracorporeal membrane
oxygenation, ESRD end-stage
renal disease, ICU intensive care
unit, IVIG intravenous
immunoglobulin,VAD ventricular
assist device
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indications for MCS, the rationale being that improving car-
diac output will improve renal perfusion and consequently
ensure good renal function. Sometimes, it may be necessary
to augment MCS with RRT for a short period of time to allow
for renal recovery [34]. Veno-arterial extracorporeal membrane
oxygenation (ECMO) support in the context of little native
cardiac function provides non-pulsatile flow to the kidneys;
nevertheless, improving cardiac output and overall perfusion is
most commonly associated with renal recovery. However,
renal insufficiency and concomitant need for dialysis, while
mechanically bridged to HT, is an important risk factor for
decreased survival before and after transplant [33, 35–37].
Lately, MCS with newer ventricular assist devices (VAD),
such as the Berlin Heart EXCOR device, offers paracorporeal,
pneumatically driven, pulsatile assistance to the circulation
[38–40]. In these critically ill children, a mild to moderate
degree of renal failure is commonly seen in the pre-
implantation period; not infrequently, new onset renal failure
may be seen post-implantation. This is most often related to
the precarious haemodynamics and poor renal perfusion pre-
and peri-implantation of the device. Children with complex
CHD and, in particular, those following single ventricle palli-
ation have higher morbidity and mortality following implan-
tation of the Berlin Heart EXCOR device [41, 42]. In a recent
study by Almond et al. of children in the USA undergoing
Berlin Heart EXCOR support as a bridge to transplantation,
renal function (measured by GFR adjusted for age) at the time
of implantation was the single strongest predictor for mortality
while on the device [38].
In a single-centre study, Prodhan et al. compared the effect
of MCS on renal function and found that there was a steady
early improvement in eGFR in the VAD-supported group and
the ECMO+VAD group which was, however, not sustained,
with a subsequent decline of renal function seen over the
length of support. In contrast, in the ECMO group, the im-
provement in eGFR continued until day 28 of support [43].
Registry-based studies have shown that the need for ECMO at
the time of being listed for HT is an important risk factor for
peri-operative renal failure [8] as well as for subsequent de-
velopment of ESRD [5]. Tang et al. reported that the need for
ECMO, ventilator and inotropic support and a primary diag-
nosis of CHD at listing increased the risk for peri-operative
renal failure [8]. Lee et al. also reported that the need for ICU
and ECMO and for pre-transplant dialysis were risk factors for
ESRD and CRI, respectively [5]. These factors reflect the
degree of clinical severity and highlight the level of depen-
dency on critical care interventions, which are crucial for
successful transplant outcome.
Chronic renal dysfunction
Late after transplant Chronic renal dysfunction in paediatric
HT recipients is common, and is slowly progressive after an
initial, early decline. The cumulative effect of total CNI ex-
posure after transplant leads to renal tubular atrophy and
interstitial fibrosis, resulting in a gradual and progressive
decline in renal function [12, 44, 45].
Immunosuppressive therapy and effects on kidney function
Calcineurin inhibitors The advent of agents such as cyclo-
sporine A and tacrolimus in post-transplant immunosup-
pression has revolutionized survival in transplant recipi-
ents; both of these drugs, however, are associated with
direct nephrotoxicity. It is very common for transplant re-
cipients to be on CNI agents at the 1- and 5-year follow-up
[3]. Both cyclosporine A and tacrolimus cause renal ischae-
mia due to afferent arteriolar vasoconstriction through acti-
vation of the intra-renal renin–angiotensin system, as well
as imbalances between prostaglandin E2 and thromboxane
A2 effects. In an elegant review, Di Filippo et al. describe
these pathophysiological mechanisms in detail [22]. Vari-
ous other postulated mechanisms include an increase in
endothe l in -1 (a poten t vasocons t r i c tor caus ing
tubulointerstitial fibrosis) and a decrease in the production
of nitric oxide (a vasodilator). Chronic ischaemia causes
in t ra - rena l overexpress ion and upregula t ion of
transforming growth factor beta 1, which in turn promotes
glomerulosclerosis and tubular interstitial fibrosis. Various
gene polymorphisms may contribute to the individual var-
iation in CNI-induced nephrotoxicity [46]. Overproduction
of angiotensin II associated with the genotype of the
angiotensin-converting enzyme might be associated with
poor prognosis. Other indirect mechanisms for CNI neph-
rotoxicity have also been implicated, such as thrombotic
micro-angiopathy, sodium retention, hypertension, dyslip-
idemia (cyclosporine A effect) and diabetes (tacrolimus
effect) [7, 19, 47].
When does toxicity occur? Is it dose dependent? Does early
high dose matter? Is it related to duration of exposure? Is there
a difference between CNIs? Is there any reversibility possible?
Two distinct patterns of cyclosporine A nephrotoxicity have
been characterized in adult studies in the immediate post-
operative and long-term follow-up periods after HT [44].
Moderate azotemia leading to AKI has been shown to be
significantly more common in the first post-operative week
in cyclosporine A-treated recipients than in patients treated
with other agents, such as azathioprine [44], and is worse with
intravenous cyclosporine A administration [14]. Although
both occur with high prevalence, the early form does not
appear to be a specific risk factor for the late form.
Nephrotoxicity with cyclosporine A is considered to be
dose-dependent, and high early exposure leads to a progres-
sive decline in renal function, which persists even after
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subsequent reduction in cyclosporine A dose [26, 48]. Al-
though with lower dosage, the degree of renal impairment
may be lower, the pathological changes in the kidney, as seen
on biopsies, remain the same regardless of dose [45]. While
CNIs have been implicated in renal insufficiency post-HT,
some studies have failed to show a direct correlation between
renal dysfunction and cyclosporine A or tacrolimus levels or
doses, suggesting that these drugs may not be the sole factor
responsible for evolving renal dysfunction post-transplant [49,
50]. In the ISHLT Fifteenth Official Paediatric Registry Re-
port 2012, the type of CNI selected had no demonstrable
influence on late renal function [3]. However, Pradhan et al.
reported that higher tacrolimus trough levels over the first
6 months had a significant negative correlation with GFR %.
Although these authors found the same correlation with cy-
closporine A levels, it did not reach statistical significance [9].
Hornung et al., in an earlier study, showed that the 2-month
cyclosporine A trough levels predicted lower GFR in the first
year after transplant [26]. Similarly, Bharat et al. showed that
the higher maximum cyclosporine A and tacrolimus dosage in
the first 2 months post-transplant were both associated with
declining GFR and increasing probability of an abnormal
GFR over time [10].
Tacrolimus is being increasingly used as an alternative to
cyclosporine A in paediatric HT patients [51]. Unlike cyclo-
sporine A [52], it does not cause gingival hyperplasia or
hirsuitism and has been shown to have superior efficacy in
paediatric HT recipients [47]. In a longitudinal study of renal
function in paediatric renal transplants, tacrolimus has been
shown to be superior to cyclosporine A, and recipients had
significantly better eGFR at 1, 2, 3 and 4 years post-transplant
[53]. Initial studies showed that cyclosporine A-induced renal
toxicity was higher with tacrolimus [51], but further studies
have not found this association [17]. English et al. compared
the nephrotoxicity of tacrolimus and cyclosporine A in 123
children followed at two HT centres over a 7-year period and
found no differences in the decline of calculated creatinine
clearance between the two groups [17]. However, hyperten-
sion, an important contributory factor to the development of
CRI, was lower in those treated with tacrolimus [51].
CNI-induced nephrotoxicity increases with duration of
exposure and has limited potential for reversibility [26, 48].
The younger transplant recipients, who are going through the
normal phase of maturation of renal function, may thus be
more vulnerable to the effects of decreased renal perfusion in
the peri-operative period. In adults, reduction of the mean
cyclosporine A dosage from 5.3 ± 0.7 to 2.3 ± 0.3 mg/kg/
day between 9 and 21 months after transplantation with con-
current azathioprine therapy led to an improvement of renal
function [44]. Some studies have reported that there may even
be a partial improvement in renal function after elimination or
dose reduction of CNIs even after years of use [54–56].
However, this result has not been consistently shown in other
adult and paediatric studies, where the early loss of renal
function was irreversible and did not improve despite substi-
tution or reduction of CNI target levels [17, 48, 49].
Other co-morbid factors contributing to CRI
Other associated medical conditions, such as hypertension [8,
17, 30, 57], diabetes [8, 58, 59] and hyperlipidaemia, may
contribute to on-going renal dysfunction and add to the cu-
mulative burden of renal insufficiency in the post-transplant
phase.
Predictive factors (pre- and post-transplant) for chronic
renal dysfunction and outcome
The degree of pre-operative worsening renal dysfunction has
been shown to be a significant factor for in-hospital mortality,
but not for late post-transplant mortality. Rajagopal et al.
showed that worsening renal function from the time of listing
to time of transplantation, as defined by AKIN guidelines, was
associated with early in-hospital mortality, but not with late
post-transplant mortality [31]. These authors found that those
with mild, moderate and severe degree of worsening renal
dysfunction had adjusted odds ratios of 2.1, 2.7 and 3.6 for in-
hospital mortality, respectively [31]. In adults, pre-transplant
serum creatinine and renal indices have been found to have
limited predictive value on late outcome after a HT operation
[49, 60]. In the most recent ISHLT Registry report, pre-
transplant renal support and pre-transplant creatinine were
identified to be significant risk factors for 1-year mortality
after HT [3].
In a recent national UNOS Registry-based study of HT
recipients with peri-operative renal failure, Tang et al. found
worse survival outcomes for those that needed pre- and post-
transplant dialysis; significant risk factors were primary diag-
nosis of CHD, Hispanic ethnicity and requirement for post-
transplant dialysis [8]. This peri-operative renal failure ap-
peared to have the most impact on survival during the first
6 months after transplant [8]. However, the authors were not
able to test the correlation between the duration of RRT and
subsequent outcome.
Although eGFR at transplant has not been shown to be a
predictive factor for later long-term renal dysfunction or out-
come [6, 31], those that develop CRI post-HT have been
shown to have a significantly higher (9-fold) risk of death
[5]. In one study, post-transplantation renal insufficiency at
6 months predicted a ninefold increased risk for developing
CKD at 5 years [27]. Similarly, another series showed that
decreased eGFR at 1-year post-HT, but not at HT, predicted
the onset of late renal dysfunction [6]. In a 10-year national
cohort study of paediatric HT recipients with a mean follow-
up of 7 years, the significant risk factors identified for CRI
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were pre-transplant dialysis, hypertrophic cardiomyopathy,
African-American race and previous transplant; those for
ESRD were hypertrophic cardiomyopathy, pre-transplant di-
abetes, African-American race and intensive care unit (ICU)
stay or ECMO at the time of transplant (the latter is suggestive
of haemodynamic instability) [5]. Increased risk of late renal
dysfunction has also been reported in black people, those with
rejection associated with haemodynamic compromise and
those with the lowest quartile of eGFR >60 mL/min/1.73 m2
at 1 year post-HT [6]. In adults, post-HT hypertension has
been found to be a predictor of renal insufficiency [61, 62].
Some studies have reported that higher maximum cyclo-
sporine A and tacrolimus dosage in the first 6 months post-
transplant is associated with declining GFR and an increasing
probability of an abnormal GFR over time [9, 10, 26]. In
contrast, the ISHLT 2012 report showed that the type of CNI
selected had no demonstrable influence on late renal function
[3]. Differences in CNI target levels and a higher probability
of an abnormal renal function could be the influenced by the
different immunosuppression regimens employed in different
eras, as shown by Bharat et al. (higher in those transplanted
before 1997) [10] and Feingold et al. (higher in those
transplanted before 1999) [6].
Thus, in summary, among the many registry-based and
single-centre studies on renal failure post-HT mentioned
above, only few factors have been consistently identified to
be of predictive value for identifying chronic renal dysfunc-
tion and subsequent outcome (see Table 1). In addition, there
are some conflicting reports. Two papers have shown that
younger age at HT is associated with late renal dysfunction
[9, 27]; another, however, has shown that a transplant age of
<2 months is associated with increasing GFR and decreasing
probability of an abnormal GFR over time [10], whereas yet
another has shown no association [5]. Similarly, gender has
been shown to be a significant factor in one study, with
females having a higher probability of an abnormal late
GFR [10], which has not been borne out in other studies [5,
9, 27].
Diagnosis and management of transplant recipients
with renal insufficiency
Measurement of renal function
Early diagnosis of renal impairment is important so that inter-
ventions may be instituted to prevent further ongoing damage.
Regular monitoring and screening of renal function with
serum creatinine and calculation of eGFR (when abnormal),
formal GFR measurement, renal ultrasound scan, urine anal-
ysis for proteinuria and albumin/creatinine ratio are recom-
mended. Most transplant centres maintain an institutional
protocol for monitoring, which includes renal function. The
ISHLT guidelines recommend that eGFR should be done and
urinalysis obtained at least yearly in paediatric HT recipients
[63]. Close surveillance and monitoring of CNI drug levels,
with frequent adjustment to target therapeutic range, is vital.
Regular screening for hypertension, diabetes and hyperlipid-
aemia is an integral part of post-transplant management [63].
In addition to regular monitoring, tests such as ambulatory
blood pressure, oral glucose tolerance test and hyperlipidemia
screen are recommended on an annual basis.
Management of AKI
Acute kidney injury in the peri-operative period or anytime in
the post-transplant period is treated with diuretics, usually
loop diuretics such as furosemide, either intermittently or as
an infusion with careful fluid restriction, while maintaining
euvolemia and avoiding hypotension (see Fig. 2). Monitoring
of central venous pressure (CVP) and targeting optimum
haemodynamics to ensure renal perfusion is vital. The CVP
should be maintained between 5–12 mmHg, a level that
provides adequate cardiac filling pressures without causing
right ventricular overload [63, 64]. In the acute phase, early
continuous RRT is important to prevent fluid overload and to
maintain optimum renal support. If the recipient develops
anuria or oliguria or has a sharp rise in serum creatinine within
2–4 h after HT, then early continuous RRT must be instituted
[63]. Similarly, if CVP remains elevated (>20 mmHg) despite
pharmacologic interventions, continuous RRT must be com-
menced. Continuous RRT provides several advantages in
critically ill post-transplant patients: (1) it can be successfully
used even in haemodynamically unstable patients, including
those on ECMO and fluid goals can be adjusted to suit the
patient’s clinical status; (2) as it is a continuous modality, fluid
restriction is not needed, which allows nutrition, blood prod-
ucts and medications to be provided to the patient without
worsening fluid overload [65]. It is important to avoid neph-
rotoxic drugs—in particular antibiotics. Furthermore, a delay
in the initiation of CNI therapy should be considered if there is
significant pre-operative renal insufficiency or deterioration of
kidney function during the first 2 post-operative days [63]. If
renal failure persists beyond 4–6 weeks, then intermittent
haemodialysis is an effective form of support. This modality
can provide substantial clearance in a short period of time,
thereby allowing the child freedom from the machine, and can
facilitate rehabilitation from acute illness. However, IHD is
technically challenging and requires a specialized centre with
trained personnel [65].
Management of CRI
Progressive CRI leads to many well-characterized complica-
tions, such as poor growth, anaemia, hypertension, hypercho-
lesterolaemia, secondary hyperparathyroidism with metabolic
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bone disease and electrolyte abnormalities. These need to be
managed with a good control of hypertension, use of lipid-
lowering agents and management of metabolic bone disease
(see Fig. 2). The accelerated cardiovascular disease and sodi-
um retention associated with CKD often requires maintaining
patients in a relatively volume-depleted state, which can cause
further chronic ischaemic injury to the kidney [21]. Renal
dysfunction is one of the factors that influences/contributes
to the overall net state of immunosuppression, which in turn
can predispose to an increased risk of infection [8, 66]. Inter-
ventions that have been proven to slow progression of CKD in
the general population, such as management of hypertension
and strict management of diabetes, must be instituted [63].
Renal dietetic review to advise on high calorie, adequate
protein, low phosphate diet and potassium and oxalate dietary
intake is essential.
Facilitating renal recovery after transplantation
Strategies to decrease CNI exposure
Strategies to improve renal function in recipients with signif-
icant renal dysfunction are directed towards reducing or elim-
inating exposure to nephrotoxic drugs and minimizing renal
haemodynamic insults (see Fig. 2). Reducing the dose of CNI
and if possible, withdrawal while substituting with another
appropriate non-CNI agent—e.g. mTOR inhibitor (sirolimus/
everolimus)—to maintain effective immunosuppression
should be considered [56, 63, 67–71].
There have been reports that switching the adjunct drug
from azathioprine to mycophenolate mofetil has allowed low-
er trough levels of CNIs to be maintained without significant
increase in rejection [55]. More recently, the proliferation
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Fig. 2 Recommendations to
protect renal function and
facilitate renal recovery in
paediatric heart transplant
recipients. AKI Acute kidney
injury, MCS mechanical
circulatory support, CNI
calcineurin inhibitor, CKD
chronic kidney disease, CRI
chronic renal insufficiency, RRT
renal replacement therapy
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signal inhibitors sirolimus and everolimus have been used as
CNI-sparing agents for immunosuppression in HT patents
who have renal dysfunction without significant increase in
rejection episodes [56, 67, 71, 72]. Two strategies have been
used—sirolimus combined with low-dose calcineurin inhibi-
tor and sirolimus as a replacement for calcineurin inhibitor.
Both strategies have been reported to result in improved renal
function, but caution has to be maintained with when
sirolimus is administered without CNI as this therapy may
be associatedwith increased rejection episodes [73]. It appears
that using tacrolimus and mycophenolate mofetil provides a
safer alternative to the various immunosuppressive regimens
[69, 73, 74]. Basiliximab, a chimeric monoclonal antibody
against CD25 (interleukin 2 receptor alfa) has potential ad-
vantages in the treatment of patients with renal impairment.
Ford et al. reported that basiliximab given on Day 0 and Day 4
after transplantation in a group of ill children with pre- or post-
operative renal dysfunction along with reduction or withdraw-
al of CNIs was well tolerated, with a low incidence of rejec-
tion [75]. Post-transplant ECMO may reduce the efficacy of
basiliximab [75].
In summary, avoidance of overimmunosuppression, judi-
cious use of steroids and CNI, minimization of doses where
possible, and possibly the use of m-TOR inhibitors, are crucial
in preventing and/or ameliorating renal dysfunction. In addi-
tion, careful avoidance of drugs that may alter metabolism of
CNI and increase their renal toxicity is essential [76]. Further-
more, it is important to minimize or avoid exposure to other
nephrotoxic drugs, such as aminoglycosides, amphotericin
and ganciclovir, that are commonly used post-transplant to
treat infections. Drug dosage needs to be adjusted for renal
failure with careful therapeutic drug monitoring.
A word of caution needs to be emphasized: the potential
risk for precipitation of rejection remains with modification of
CNI agents; therefore, all these recipients must be closely
followed to ensure effective immunosuppression. If signifi-
cant renal insufficiency persists despite CNI reduction, the
risk of precipitating rejection outweighs the benefit on renal
function, and there is little evidence to support CNI-free
regimens [22, 63].
Management of ESRD
Renal transplant
The ISHLT Fifteenth Official Paediatric Registry Report 2012
reported that 10 % of patients required RRT in the form of
dialysis or renal transplant by 15 years post-heart transplant
[3].
In keeping with the Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines, timely preparation for RRT is
essential for non-renal organ transplant recipients with
declining renal function. Sequential kidney transplantation
may be considered for ESRD in selected appropriate candi-
dates [63]. Most recipients who need RRT undergo
haemodialysis (HD) although chronic peritoneal dialysis
(PD) may also be used; however, the risk of peritonitis re-
mains [65]. Both forms of RRT are associated with an in-
creased mortality rate.
Combined or staged heart–kidney transplantation
for refractory renal dysfunction
With advances in mechanical circulatory support, multi-organ
transplantation with simultaneous combined heart-kidney
transplant has become feasible, with reasonable outcome.
Kim et al. report 2 children with end-stage heart and renal
failure who were successfully bridged to combined, single-
donor heart and kidney transplantation with mechanical cir-
culatory support [77]. Simultaneous heart and kidney trans-
plant has been reported in 0.5 % of children (UNOS database
1982–2009) where the survival was not significantly different
from those undergoing heart transplant only [78]. Many of
these patients (34 %) were going for a heart retransplantation.
Gupta et al., in their series of recipients (UNOS database) over
a 10-year period, found that the 1-year and 5-year survival
after renal transplant was comparable to those who did not
have a renal transplant [79].
Prevention, intervention and education, practice
and policy
Potential renoprotective strategies should be pre-emptively
instituted from the peri-transplant phase (see Fig. 2). Careful
attention to minimize peri-transplant renal injury, such as the
avoidance of nephrotoxic drugs while awaiting transplant and
optimization of peri-operative haemodynamics to prevent low
cardiac output state and multiple organ failure, is important [8,
63, 64].
Certain high-risk groups, such as those with CHD and
hypertrophic cardiomyopathy, may be more susceptible for
renal dysfunction after HT [5, 8, 33]. Excessive diuresis
leading to dehydration and effective volume contraction must
be avoided while maintaining a careful watch on nephrotoxic
medications.
Regular screening of renal function at 1, 3 and 12 months,
and yearly thereafter, is recommended [63, 80]. Early involve-
ment of paediatric nephrologists in the management of renal
dysfunction, especially when there is renal dysfunction and a
GFR of <90 mL/min/1.73 m2, presence of micro-albuminuria
(urine albumin/creatinine 30–300 mg/g) and persistent hyper-
tension, is recommended [63, 80]. Early detection allows the
possibility to slow CKD progression or even restore function
with effective management. Physicians must focus on the
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prevention of CKD progression, as strategies to slow progres-
sion are more effective if started early.
Modifiable risk factors to prevent the progression of CKD
are control of hypertension, diabetes, hyperlipidaemia and
obesity [80–82]. Patient and parent education with regard to
diet, exercise, avoidance/cessation of smoking, careful atten-
tion to over-the-counter or non-prescription drugs with poten-
tial nephrotoxicity and awareness of important drug interac-
tions is the key to successful management. Careful and per-
haps preferential use of tacrolimus after transplantation is
important [68, 69, 74, 75, 83]. Diligent blood pressure control
with the judicious use of antihypertensive agents [81] along
with low-protein diets and statin therapy may ameliorate the
progression of CKD. The commonly used anti-hypertensive
medications are angiotensin-converting enzyme inhibitors,
calcium channel blockers [84] and angiotensin II receptor
blockers but a newer agent—aliskiren, a direct renin antago-
nist—has been used to effectively control blood pressure
resulting in slower progression of CKD [85].
Research horizons
A newer endogenous marker of GFR, cystatin C (a low-
molecular-weight protein), has been reported to be the best
non-invasive estimate for the measurement of GFR in adult
transplant patients [86, 87] and has been studied in paediatric
HT patients along with neutrophil gelatinase-associated
lipocalcin (NGAL) as a marker for AKI [88]. Cystatin C is
produced at a constant rate from all nucleated cells and is more
easily interpretable than creatinine as a single reference range
can be used for children aged >1 year. However, these tests are
expensive and as yet not readily available, and more research
is needed before they can be widely accepted into clinical use.
Multicentre randomized controlled trials are needed to support
evidence for strategies to minimize CNI-related toxicity with
alternative immunosuppressive agents without increasing the
risk of rejection and compromising safety.
Key summary points
& Peri-operative renal dysfunction is common and increases
morbidity in the ICU. Severe renal dysfunction affects
long-term survival in paediatric HT recipients.
& The loss of renal function is observed early in the first year
after transplantation and is progressive, but continues at a
slower rate with subsequent follow-up.
& The risk of CKD, ESRD increases with increasing
survival.
& Appropriate monitoring and careful surveillance with lon-
gitudinal screening is recommended to detect mild renal
insufficiency such that renoprotective measures can be
instituted.
& Institution of CNI-sparing regimens with careful monitor-
ing of drug levels and tailoring of immunosuppression can
attenuate the progression of renal failure. However, there
is an increased risk of rejection and few heart transplant
patients are managed entirely CNI-free.
& A team approach with early nephrology consultation is an
essential part of long-term management.
Questions (answers are provided (following the reference
list))
Question 1: The following statements regarding measurement
of renal function are false EXCEPT
1. Serum creatinine is a reliable screening tool.
2. eGFR estimation by Schwartz formula is accurate in infants.
3. eGFR overestimates the degree of renal dysfunction in
transplant patients.
4. Serum creatinine may be normal despite renal insufficien-
cy in the pre-transplant period.
5. Micro-albuminuria is not used as a screening test for
chronic kidney disease.
Question 2: The following statements regarding CRI post-
transplant are true EXCEPT
1. Peri-operative renal dysfunction has an impact on post-
transplant CRI and mortality.
2. Peri-operative AKI may get better in certain HT patients
with better haemodynamics
3. Chronic calcineurin inhibitor exposure is the most com-
mon cause for progressive CRI after transplant.
4. Hypertension and hyperlipidaemia need to be controlled
to minimise progression of CKD.
5. Risk of CRI decreases with increasing post-transplant
survival.
Question 3: The following statements regarding risk factors
for later renal dysfunction for thoracic transplant recipients are
true EXCEPT
1. ISHLT Report 2012 did not find any association with type
of CNI and later renal dysfunction.
2. Earlier era of transplantation has been shown to have a
higher risk
3. Certain subgroups such as those with congenital heart
disease are at higher risk.
4. Prolonged need for Dialysis pre- or post-transplant has
been reported to be a significant risk factor for mortality
after HT.
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5. The number of rejection episodes in recipient has no
influence on long-term CRI if appropriately managed.
Question 4: The following statements regarding CNI are
true EXCEPT
1. CNI cause direct nephrotoxicity
2. CNI nephrotoxicity is dose dependent, but the effect
modified by individual genetic susceptibility
3. CNI nephrotoxicity decreases with duration of exposure
4. CNI toxicity has limited potential for reversibility
5. Early high exposure leads to progressive decline in renal
function
Question 5: Strategies to facilitate renal recovery include
the following EXCEPT
1. Minimization of CNI dosage
2. Aggressive management of hyperlipidaemia
3. Aggressive management of hypertension
4. Vigilance for adverse drug interactions
5. Aggressive diuresis and chronic effective volume
contraction
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